Preclinical data support clear differentiation of Adcentrx’s platform and lead program, ADRX-0706, currently being evaluated in a Phase 1a/b clinical trial SAN DIEGO, April 1, 2024 /PRNewswire/ — Adcentrx Therapeutics (“Adcentrx”), a biotechnology company revolutionizing Antibody-Drug…